BR112018008799A2 - método de prognóstico - Google Patents
método de prognósticoInfo
- Publication number
- BR112018008799A2 BR112018008799A2 BR112018008799A BR112018008799A BR112018008799A2 BR 112018008799 A2 BR112018008799 A2 BR 112018008799A2 BR 112018008799 A BR112018008799 A BR 112018008799A BR 112018008799 A BR112018008799 A BR 112018008799A BR 112018008799 A2 BR112018008799 A2 BR 112018008799A2
- Authority
- BR
- Brazil
- Prior art keywords
- bcma
- sample
- measuring
- expression
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 abstract 4
- 208000034578 Multiple myelomas Diseases 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 2
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001116—Receptors for cytokines
- A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dispersion Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
trata-se de métodos para determinar um prognóstico de mieloma múltiplo em um paciente medindo-se a expressão de bcma em uma amostra. proporcionam-se, também, métodos para tratar mieloma múltiplo medindo-se a expressão de bcma em uma amostra e administrando-se uma quantidade eficaz de uma proteína de ligação ao antígeno que se liga a bcma. proporcionam-se, também, kits para medir a expressão de bcma em uma amostra.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248595P | 2015-10-30 | 2015-10-30 | |
US201562261957P | 2015-12-02 | 2015-12-02 | |
PCT/IB2016/056511 WO2017072716A1 (en) | 2015-10-30 | 2016-10-28 | Prognostic method |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018008799A2 true BR112018008799A2 (pt) | 2019-01-15 |
Family
ID=57249846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018008799A BR112018008799A2 (pt) | 2015-10-30 | 2016-10-28 | método de prognóstico |
Country Status (10)
Country | Link |
---|---|
US (1) | US11353458B2 (pt) |
EP (1) | EP3368903A1 (pt) |
JP (1) | JP2019501369A (pt) |
KR (1) | KR20180077193A (pt) |
CN (1) | CN108474793A (pt) |
AU (1) | AU2016347516A1 (pt) |
BR (1) | BR112018008799A2 (pt) |
CA (1) | CA3002759A1 (pt) |
RU (1) | RU2018119706A (pt) |
WO (1) | WO2017072716A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017123741A1 (en) | 2016-01-12 | 2017-07-20 | Institute For Myeloma & Bone Cancer Research | Improved methods for monitoring immune status of a subject |
EP3619535A4 (en) * | 2017-05-05 | 2020-12-30 | University of Technology Sydney | CANCER PROGNOSIS PROCESS |
WO2018231944A1 (en) | 2017-06-13 | 2018-12-20 | Berenson James R | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
CN110372796B (zh) * | 2018-04-12 | 2023-05-02 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
CA3118191A1 (en) * | 2018-10-31 | 2020-05-07 | Glaxosmithkline Intellectual Property Development Limited | Methods of treating cancer |
WO2020088164A1 (zh) * | 2018-11-01 | 2020-05-07 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
AU2020270298A1 (en) | 2019-05-07 | 2021-12-23 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Engineered immune cell targeting BCMA and use thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
ATE459651T1 (de) | 2001-08-10 | 2010-03-15 | Univ Aberdeen | Antigenbindende domäne aus fisch |
US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
LT3415531T (lt) * | 2011-05-27 | 2023-09-25 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) – surišantys baltymai |
CN104254778A (zh) * | 2012-02-10 | 2014-12-31 | 西雅图遗传学公司 | Cd30+癌症的检测和治疗 |
US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
CA2900529A1 (en) * | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
-
2016
- 2016-10-28 WO PCT/IB2016/056511 patent/WO2017072716A1/en active Application Filing
- 2016-10-28 BR BR112018008799A patent/BR112018008799A2/pt not_active Application Discontinuation
- 2016-10-28 CA CA3002759A patent/CA3002759A1/en not_active Abandoned
- 2016-10-28 KR KR1020187014474A patent/KR20180077193A/ko unknown
- 2016-10-28 AU AU2016347516A patent/AU2016347516A1/en not_active Abandoned
- 2016-10-28 JP JP2018521885A patent/JP2019501369A/ja not_active Ceased
- 2016-10-28 US US15/771,622 patent/US11353458B2/en active Active
- 2016-10-28 EP EP16791700.4A patent/EP3368903A1/en not_active Withdrawn
- 2016-10-28 RU RU2018119706A patent/RU2018119706A/ru not_active Application Discontinuation
- 2016-10-28 CN CN201680073476.5A patent/CN108474793A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019501369A (ja) | 2019-01-17 |
CA3002759A1 (en) | 2017-05-04 |
US11353458B2 (en) | 2022-06-07 |
US20180306791A1 (en) | 2018-10-25 |
RU2018119706A (ru) | 2019-12-02 |
KR20180077193A (ko) | 2018-07-06 |
EP3368903A1 (en) | 2018-09-05 |
AU2016347516A1 (en) | 2018-05-10 |
WO2017072716A1 (en) | 2017-05-04 |
CN108474793A (zh) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018008799A2 (pt) | método de prognóstico | |
BR112018011336A2 (pt) | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
BR112019003129A2 (pt) | composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer. | |
BR112017017025A2 (pt) | métodos e composições para analizar componentes celulares | |
BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
BR112018000768A2 (pt) | anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos | |
BR112017020893A2 (pt) | método para o tratamento de câncer | |
BR112016027475A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático | |
BR112017014551A2 (pt) | ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit? | |
BR112017012222A2 (pt) | métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit. | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
BR112016007348A2 (pt) | membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer | |
BR112016019836A2 (pt) | método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito | |
EA201690465A1 (ru) | Способ оценки эффектов композиции, содержащей микроорганизмы, на кишечную микробиоту | |
EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
BR112017004056A2 (pt) | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo | |
BR112016019740A2 (pt) | monitoramento do estado de inflamação | |
BR112016024730A2 (pt) | dispositivo, método e conjunto de análise imunocromatográfica | |
BR112019006862A2 (pt) | dispositivo de análise e método para testagem de uma amostra | |
BR112018003147A2 (pt) | anticorpos e testes para detecção de cd37 | |
BR112019010034A2 (pt) | fator viii alvejado de hemácia e método de uso do mesmo | |
GB2552271A (en) | A method for diagnosing lung cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 62/261,957 DE 02/12/2015 REIVINDICADA NO PCT/IB2016/056511 DE 28/10/2016 POR CUMPRIMENTO INSATISFATORIO DA EXIGENCIA PUBLICADA NA RPI 2495 DE 30/10/2018 PARA APRESENTACAO DE DOCUMENTO DE CESSAO CORRETO. NAO HOUVE APRESENTACAO DA CESSAO DA EMPRESA UCL CANCER INSTITUTE PARA A EMPRESA DEPOSITANTE NO PAIS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED . A PESAR DA DEPOSITANTE NA FASE NACIONAL SER CO-PROPRIETARIA DO PEDIDO UTILIZADO COMO PRIORIDADE, ELA PRECISA TER AUTORIZACAO DOS DEMAIS DEPOSITANTES PARA UTILIZA-LA EM UM PEDIDO DIVERSO. |
|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |